{"id":2929,"date":"2026-08-26T01:06:40","date_gmt":"2026-08-26T00:06:40","guid":{"rendered":"https:\/\/officialcorepeptides.brandloom.net\/en\/?post_type=product&p=2929"},"modified":"2026-08-26T01:06:40","modified_gmt":"2026-08-26T00:06:40","slug":"buy-pentapeptide-18-in-switzerland","status":"publish","type":"product","link":"https:\/\/officialcorepeptides.ch\/en\/product\/buy-pentapeptide-18-in-switzerland\/","title":{"rendered":"Pentapeptide-18 (Leuphasyl) (200MG)"},"content":{"rendered":"

What Is Pentapeptide-18?<\/h2>\n

Pentapeptide-18, commercially known as Leuphasyl, is a synthetic neuropeptide composed of five amino acids with the sequence Tyr-D-Ala-Gly-Phe-Leu. This sequence is a modification of the naturally occurring opioid peptide Leu-enkephalin (Tyr-Gly-Gly-Phe-Leu), where the second glycine is replaced with D-Alanine. This D-Ala substitution prevents rapid enzymatic cleavage by epidermal proteases, significantly extending the peptide’s bioavailability and stability in research settings.<\/p>\n

As a synthetic enkephalin analog, Pentapeptide-18 has attracted research interest for its ability to bind to enkephalin (opioid) receptors on the surface of nerve cells. Researchers investigate this peptide for its neuromodulatory properties, particularly its effects on neurotransmitter release and neuronal signaling. For those looking to buy Pentapeptide-18 in Switzerland<\/strong>, Core Peptides offers high-quality research-grade material for laboratory applications.<\/p>\n

Pentapeptide-18 Research Overview<\/h2>\n

Pentapeptide-18 belongs to the class of enkephalin analogs\u2014synthetic peptides that mimic the structure and function of endogenous opioid peptides. The peptide’s design incorporates a D-Ala substitution at position 2, a common modification in enkephalin research that enhances resistance to enzymatic degradation while preserving receptor-binding activity.<\/p>\n

Research interest in Pentapeptide-18 centers on its ability to modulate neurotransmitter release through enkephalin receptor activation. Studies have demonstrated that Pentapeptide-18 binds to enkephalin receptors (primarily \u03b4-opioid receptors) on neuronal membranes, activating inhibitory Gi-proteins that suppress voltage-gated calcium channels and reduce acetylcholine release. This mechanism positions Pentapeptide-18 as a valuable research tool for investigating neuromodulation, synaptic transmission, and G-protein-coupled receptor signaling.<\/p>\n

When researchers choose to buy Pentapeptide-18 in Switzerland<\/strong> for laboratory studies, they gain access to a compound that may help elucidate mechanisms of neurotransmitter regulation, receptor-ligand interactions, and neuronal signaling pathways at the molecular level.<\/p>\n

How Does Pentapeptide-18 Work?<\/h2>\n

Pentapeptide-18 exerts its biological effects through enkephalin receptor activation and subsequent modulation of neurotransmitter release. The peptide’s mechanism involves several interconnected steps.<\/p>\n

Enkephalin Receptor Binding<\/h3>\n

Pentapeptide-18 binds to enkephalin receptors\u2014primarily \u03b4-opioid receptors\u2014on the surface of neuronal cells. As a structural analog of Leu-enkephalin, the peptide shares the receptor-binding characteristics of endogenous enkephalins, allowing it to act as a receptor agonist at these sites.<\/p>\n

Gi-Protein Activation<\/h3>\n

Upon receptor binding, Pentapeptide-18 activates inhibitory Gi-proteins coupled to the enkephalin receptor. This activation triggers a cascade of intracellular signaling events characteristic of G-protein-coupled receptor (GPCR) activation.<\/p>\n

Calcium Channel Modulation<\/h3>\n

Activated Gi-proteins subsequently suppress voltage-gated calcium channels on the neuronal membrane. This calcium channel inhibition reduces calcium influx into the presynaptic terminal, which in turn decreases the release of neurotransmitters into the synaptic cleft.<\/p>\n

Reduced Neurotransmitter Release<\/h3>\n

Consequently, Pentapeptide-18 reduces the release of acetylcholine (ACh) from neuronal cells. This mechanism operates without interfering with the SNARE complex\u2014the molecular machinery responsible for synaptic vesicle fusion\u2014providing a distinct pathway for modulating synaptic transmission.<\/p>\n

Researchers who buy Pentapeptide-18 in Switzerland<\/strong> for research purposes can investigate these mechanisms across diverse experimental models of neuromodulation and receptor signaling.<\/p>\n

Why Is Pentapeptide-18 Studied?<\/h2>\n

Researchers study Pentapeptide-18 primarily for its potential relevance to neuromodulation, receptor signaling, and neurotransmitter research. The peptide’s ability to selectively activate enkephalin receptors and modulate neurotransmitter release makes it a valuable tool for understanding the molecular basis of synaptic transmission and neuronal communication.<\/p>\n

The peptide’s connection to the endogenous opioid system has made it a focus of neuropharmacological research. Preclinical studies have explored Pentapeptide-18’s effects on neurotransmitter release, receptor binding kinetics, and neuronal signaling in various experimental models.<\/p>\n

Moreover, researchers study Pentapeptide-18 in the context of GPCR signaling and drug development. As a stable enkephalin analog with enhanced enzymatic resistance, Pentapeptide-18 serves as a useful model compound for investigating receptor-ligand interactions and structure-activity relationships in the opioid receptor system.<\/p>\n

Researchers who buy Pentapeptide-18 in Switzerland<\/strong> from Core Peptides can incorporate this peptide into their studies on enkephalin receptor biology, neuromodulation, and neurotransmitter regulation.<\/p>\n

Pentapeptide-18 Research Areas<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n
Research Area<\/th>\nDescription<\/th>\n<\/tr>\n<\/thead>\n
Enkephalin Receptor Binding<\/strong><\/td>\nInvestigating Pentapeptide-18’s affinity and selectivity for opioid receptor subtypes<\/td>\n<\/tr>\n
Neurotransmitter Modulation<\/strong><\/td>\nStudying Pentapeptide-18’s effects on acetylcholine and other neurotransmitter release<\/td>\n<\/tr>\n
Gi-Protein Signaling<\/strong><\/td>\nExamining Pentapeptide-18’s activation of inhibitory G-protein signaling pathways<\/td>\n<\/tr>\n
Calcium Channel Regulation<\/strong><\/td>\nExploring Pentapeptide-18’s modulation of voltage-gated calcium channels<\/td>\n<\/tr>\n
Neuromuscular Research<\/strong><\/td>\nPreclinical research into Pentapeptide-18’s effects at the neuromuscular junction<\/td>\n<\/tr>\n
Receptor-Ligand Interactions<\/strong><\/td>\nInvestigating the molecular basis of enkephalin receptor binding and activation<\/td>\n<\/tr>\n
GPCR Signaling<\/strong><\/td>\nStudying Pentapeptide-18 as a model compound for G-protein-coupled receptor research<\/td>\n<\/tr>\n
Neuronal Signaling<\/strong><\/td>\nExploring Pentapeptide-18’s effects on neuronal communication and synaptic transmission<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Scientific Research on Pentapeptide-18<\/h2>\n

Researchers have conducted scientific studies on Pentapeptide-18 in both in vitro and ex vivo settings, deriving evidence from cell cultures, receptor-binding assays, and tissue samples. The peptide originates from the enkephalin analog research program, which has investigated modified opioid peptides for several decades.<\/p>\n

In Vitro Evidence<\/h3>\n

In vitro studies using receptor-binding assays have demonstrated that Pentapeptide-18 binds to enkephalin receptors on neuronal membranes, activating inhibitory Gi-proteins that suppress voltage-gated calcium channels. The D-Ala substitution at position 2 provides resistance to enzymatic degradation by epidermal proteases, significantly extending the peptide’s stability in biological environments.<\/p>\n

Studies have shown that Pentapeptide-18 reduces acetylcholine release through a pre-synaptic mechanism involving G-protein-mediated calcium channel inhibition. This mechanism does not interfere with the SNARE complex, distinguishing it from other neuromodulatory pathways.<\/p>\n

Spectroscopic and Molecular Studies<\/h3>\n

Researchers have characterized Pentapeptide-18 using spectroscopic techniques and molecular interaction analysis. These studies have provided insights into the peptide’s structural properties and its molecular interactions with target receptors. Molecular docking and molecular dynamics simulations have been employed to investigate the binding mode of Pentapeptide-18 to enkephalin receptors.<\/p>\n

Clinical and Human Studies<\/h3>\n

Pentapeptide-18 has been investigated in human studies for its effects on expression lines and wrinkles. An active-controlled trial compared a cream containing 5% leuphasyl solution (0.05%) with other formulations, finding mean wrinkle reductions of 11.64%. Another study reported up to 35% reduction in wrinkle depth in the frontal region after 2 months of treatment. These studies suggest a synergistic effect between Leuphasyl and other peptides.<\/p>\n

Nevertheless, researchers should note that Pentapeptide-18 has primarily been studied in the context of cosmetic applications, and mechanistic research has largely occurred in preclinical settings. Findings should be interpreted as experimental rather than established. Scientists who buy Pentapeptide-18 in Switzerland<\/strong> should remain aware of these evidence considerations.<\/p>\n

Pentapeptide-18 Compared With Related Peptides<\/h2>\n\n\n\n\n\n\n\n\n\n
Peptide<\/th>\nRelationship to Pentapeptide-18<\/th>\nKey Differences<\/th>\n<\/tr>\n<\/thead>\n
Leu-enkephalin<\/strong><\/td>\nParent compound; Pentapeptide-18 is a modified analog<\/td>\nLeu-enkephalin has Tyr-Gly-Gly-Phe-Leu; Pentapeptide-18 has D-Ala substitution at position 2 for enhanced stability<\/td>\n<\/tr>\n
Argireline (Acetyl Hexapeptide-3)<\/strong><\/td>\nBoth studied for neuromodulation and neurotransmitter research<\/td>\nArgireline inhibits SNARE complex; Pentapeptide-18 targets enkephalin receptors and Gi-protein signaling<\/td>\n<\/tr>\n
Acetyl Hexapeptide-1<\/strong><\/td>\nBoth are neuropeptides studied for neuromodulation<\/td>\nDifferent sequences and mechanisms; both investigated for neurotransmitter modulation<\/td>\n<\/tr>\n
Palmitoyl Tetrapeptide-7<\/strong><\/td>\nBoth are synthetic peptides with skin research applications<\/td>\nPalmitoyl Tetrapeptide-7 targets IL-6 and matrix remodeling; Pentapeptide-18 targets enkephalin receptors<\/td>\n<\/tr>\n
GHK-Cu<\/strong><\/td>\nBoth studied for skin and cellular research<\/td>\nGHK-Cu is a copper complex with different mechanism; Pentapeptide-18 is an enkephalin receptor agonist<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Research Applications<\/h2>\n

Researchers utilize Pentapeptide-18 in a variety of laboratory research applications, primarily in the fields of neuropharmacology, receptor biology, and cellular signaling. Key research applications include:<\/p>\n